

CO.DON AG and Haemo Pharma GmbH sign contract for the distribution of Spherox in Austria

Berlin / Teltow, 05 September 2018 – Yesterday CO.DON AG and Haemo Pharma GmbH signed a contract for the exclusive distribution in Austria of the EU-authorized, cell-based pharmaceutical Spherox, initially for a period of five years. For CO.DON AG, signing the distribution agreement means contractually agreed cash flows on an ascending annual scale, totalling around EUR 1 million at minimum in the business years 2018 and 2019. CO.DON will support Haemo Pharma GmbH during the entire distribution phase and will retain defined responsibilities.

Ralf Jakobs, CEO of CO.DON AG, was very pleased with the result of the successful negotiations: “We are delighted that we and Haemo Pharma GmbH have been able to reach an effective and lucrative agreement for both of us, which will enable us and our partner to deliver an extremely successful market launch for our product in Austria and which forms the basis for a long-term partnership. Having signed this contract we are now in a position to present a stable and secure monetary result for the Austrian market too, even before the forthcoming adequate reimbursement of our product takes effect. This is in line with our strategy of only offering our product in markets with reasonable pricing and reimbursement policies.

Furthermore, we see the Austrian market as the starting point for opening up selected eastern European markets, where we will also be looking for distribution partners.”

CO.DON AG develops, produces and markets autologous cell therapies for the minimally-invasive repair of cartilage damage in the knee joint following traumatic or degenerative defects. Spherox is a cell therapy product that uses only the patient’s own cartilage cells (“autologous chondrocytes”). The treatment has been used in over 200 clinics to treat more than 14,000 patients. The company received EU marketing authorisation for Spherox in July 2017. The shares in CO.DON AG are listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227). Executive Board: Ralf M. Jakobs.

Further information is available from www.codon.de

Investor Relations and Press Contact:

Matthias Meißner, M.A.

Corporate communications / IR / PR

Tel. +49 (0)30 240352330

Fax +49 (0)30 240352309

Email: ir@codon.de